Marc Bourlière

26.2k total citations · 2 hit papers
305 papers, 8.8k citations indexed

About

Marc Bourlière is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Marc Bourlière has authored 305 papers receiving a total of 8.8k indexed citations (citations by other indexed papers that have themselves been cited), including 255 papers in Hepatology, 218 papers in Epidemiology and 41 papers in Infectious Diseases. Recurrent topics in Marc Bourlière's work include Hepatitis C virus research (221 papers), Liver Disease Diagnosis and Treatment (170 papers) and Hepatitis B Virus Studies (130 papers). Marc Bourlière is often cited by papers focused on Hepatitis C virus research (221 papers), Liver Disease Diagnosis and Treatment (170 papers) and Hepatitis B Virus Studies (130 papers). Marc Bourlière collaborates with scholars based in France, United States and Germany. Marc Bourlière's co-authors include Philippe Halfon, Stanislas Pol, Guillaume Pénaranda, Denis Ouzan, Christophe Hézode, Laurent Castéra, Victor de Lédinghen, Geoffrey Dusheiko, Christophe Renou and Jean–Pierre Bronowicki and has published in prestigious journals such as New England Journal of Medicine, Annals of Internal Medicine and Gastroenterology.

In The Last Decade

Marc Bourlière

290 papers receiving 8.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection

2009 771 citations Stanislas Pol, Jean–Pierre Bronowicki et al. profile →
Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin

2014 395 citations Marc Bourlière, Heiner Wedemeyer et al. profile →

Peers

Countries citing papers authored by Marc Bourlière

Since Specialization

Citations

This map shows the geographic impact of Marc Bourlière's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marc Bourlière with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marc Bourlière more than expected).

Fields of papers citing papers by Marc Bourlière

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marc Bourlière. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marc Bourlière. The network helps show where Marc Bourlière may publish in the future.

Co-authorship network of co-authors of Marc Bourlière

This figure shows the co-authorship network connecting the top 25 collaborators of Marc Bourlière. A scholar is included among the top collaborators of Marc Bourlière based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marc Bourlière. Marc Bourlière is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	HBsAg decline and clearance with peg-IFN therapy added to nucleos(t)ide analogues: an individual participant data meta-analysis of prospective trials (PROSPER) 2025 ·Gut ·(unknown), (unknown), Seng Gee Lim, Marc Bourlière, (unknown), Nathalie Ganne‐Carrié, Willem Pieter Brouwer, Jordan J. Feld, (unknown), J.A. Carrión, (unknown), (unknown), Scott Fung, Fabrice Carrat, Fabien Zoulim, Bettina E. Hansen, Qing Xie, Harry L.A. Janssen, Milan J. Sonneveld	1
2	JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analogue-suppressed patients with chronic hepatitis B: REEF-2 2024 ·Journal of Hepatology ·Kosh Agarwal, Marı́a Buti, Florian van Bömmel, Pietro Lampertico, Ewa Janczewska, Marc Bourlière, Thomas Vanwolleghem, Oliver Lenz, Thierry Verbinnen, Thomas N. Kakuda, Cristiana Mayer, (unknown), Daniel G. Muenz, Maria Beumont, Ronald Kalmeijer, Michael Biermer, Isabelle Lonjon‐Domanec	22
3	Bulevirtide Monotherapy Is Safe and Well Tolerated in Chronic Hepatitis Delta: An Integrated Safety Analysis of Bulevirtide Clinical Trials at Week 48 2024 ·Liver International ·Tarik Asselah, Pietro Lampertico, Soo Aleman, Marc Bourlière, Adrian Streinu‐Cercel, Pavel Bogomolov, Viacheslav Morozov, (unknown), (unknown), (unknown), Renée-Claude Mercier, (unknown), Lei Ye, John F. Flaherty, Anu Osinusi, Ben L. Da, (unknown), Audrey Lau, Maurizia Rossana Brunetto, Heiner Wedemeyer	5
4	Hepatitis C virus cure from direct‐acting antivirals and mortality: Are people with and without a history of injection drug use in the same boat? (ANRS CO22 Hepather cohort) 2023 ·Drug and Alcohol Review ·Tangui Barré, Marc Bourlière, Lucia Parlati, (unknown), Fabienne Marcellin, Camélia Protopopescu, (unknown), Carole Cagnot, Céline Dorival, Jérôme Nicol, Fabien Zoulim, Fabrice Carrat, Patrizia Carrieri, (unknown)	0
5	Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma: Real-life Data on Liver Disease, Treatment and Prognosis 2023 ·Journal of Clinical and Translational Hepatology ·Xavier Adhoute, (unknown), Guillaume Pénaranda, Thomas Wolf, Patrick Beaurain, O. Monnet, A. Laquière, (unknown), (unknown), Olivier Levrel, (unknown), (unknown), Paul Castellani, Hervé Perrier, Marc Bourlière, Rodolphe Anty	4
6	Direct, indirect and total effect of HIV coinfection on the risk of non‐liver‐related cancer in hepatitis C virus‐infected patients treated by direct‐acting antivirals: a mediation analysis 2021 ·HIV Medicine ·(unknown), Stanislas Pol, Philippe Sogni, Hélène Fontaine, Karine Lacombe, Jean‐Marc Lacombe, (unknown), Céline Dorival, Marc Bourlière, Firouzé Bani‐Sadr, Victor de Lédinghen, David Zucman, Dominique Larrey, Dominique Salmon, Fabrice Carrat, Linda Wittkop, (unknown), (unknown)	1
7	Long-term Patient-Centered Outcomes in Cirrhotic Patients With Chronic Hepatitis C After Achieving Sustained Virologic Response 2021 ·Clinical Gastroenterology and Hepatology ·Zobair M. Younossi, Andrei Racila, Andrew J. Muir, Marc Bourlière, Alessandra Mangia, Rafael Esteban, Stefan Zeuzem, Massimo Colombo, Michael P. Manns, George Papatheodoridis, Marı́a Buti, Anand P. Chokkalingam, Anuj Gaggar, Fatema Nader, Issah Younossi, Linda Henry, Maria Stepanova	10
8	Non-invasive diagnosis and follow-up of non-alcoholic fatty liver disease 2021 ·Clinics and Research in Hepatology and Gastroenterology ·Jérôme Boursier, Maéva Guillaume, (unknown), Adrien Lannes, Raluca Pais, (unknown), Bertrand Cariou, Christophe Bureau, Nathalie Ganne‐Carrié, Marc Bourlière, Victor de Lédinghen	10
9	Viral eradication is required for sustained improvement of patient‐reported outcomes in patients with hepatitis C 2018 ·Liver International ·Zobair M. Younossi, Maria Stepanova, K. Rajender Reddy, Michael P. Manns, Marc Bourlière, Stuart C. Gordon, Eugene R. Schiff, Tram T. Tran, Issah Younossi, Andrei Racila	24
10	Hepatitis C in Patients With Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes 2017 ·Clinical Infectious Diseases ·Zobair M. Younossi, Maria Stepanova, Tarik Asselah, Graham R. Foster, Keyur Patel, Norbert Bräu, Mark G. Swain, Tram T. Tran, Rafael Esteban, M. Colombo, Stephen Pianko, Linda Henry, Marc Bourlière	18
11	The impact of ledipasvir/sofosbuvir on patient‐reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study 2015 ·Liver International ·Zobair M. Younossi, Maria Stepanova, Stanislas Pol, Jean–Pierre Bronowicki, Patrizia Carrieri, Marc Bourlière	45
12	Efficacy and Safety of Faldaprevir, Deleobuvir, and Ribavirin in Treatment-Naive Patients with Chronic Hepatitis C Virus Infection and Advanced Liver Fibrosis or Cirrhosis 2014 ·Antimicrobial Agents and Chemotherapy ·Stefan Zeuzem, Vincent Soriano, Tarik Asselah, Edward Gane, Jean–Pierre Bronowicki, Peter Angus, Ansgar W. Lohse, Felix Stickel, Beat Müllhaupt, Stuart K. Roberts, Marcus Schuchmann, Michael P. Manns, Marc Bourlière, Marı́a Buti, Jerry O. Stern, (unknown), Florian Voß, John P. Sabo, Wulf O. Böcher, Federico Mensa	8
13	Retreatment with TACE: The ABCR SCORE, an aid to the decision-making process 2014 ·Journal of Hepatology ·Xavier Adhoute, Guillaume Pénaranda, (unknown), Jean‐Luc Raoul, Hervé Perrier, Olivier Bayle, O. Monnet, Patrick Beaurain, Christophe Bazin, Bernard Pol, (unknown), Paul Castellani, J.-P. Bronowicki, Marc Bourlière	117
14	1167 IL-28 GENE VARIATION PREDICTS WHO WILL RESPOND TO INTERFERON-BASED TREATMENT OF CHRONIC HEPATITIS C IN A FRENCH COHORT 2010 ·Journal of Hepatology ·Philippe Halfon, Marc Bourlière, Denis Ouzan, Christophe Renou, Claire Wartelle, Guillaume Pénaranda, (unknown), Davide Botta, Valérie Oulès, Patrizia Castellani, Isabelle Portal, Laurent Argiro, Alain Dessein	2
15	The accuracy of the FIB‐4 index for the diagnosis of mild fibrosis in chronic hepatitis B 2008 ·Alimentary Pharmacology & Therapeutics ·Vincent Mallet, Valérie Dhalluin-Venier, (unknown), Marc Bourlière, (unknown), Claude Giry, Anaïs Vallet‐Pichard, Hélène Fontaine, Stanislas Pol	91
16	Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation 2007 ·Alimentary Pharmacology & Therapeutics ·Thierry Poynard, Philippe Halfon, Laurent Castéra, Frédéric Charlotte, Brigitte Le Bail, M. Munteanu, Djamila Messous, Vlad Ratziu, Y. Benhamou, Marc Bourlière, (unknown), (unknown)	81
17	[Transmission of hepatitis B and C viruses from caregiver to patients: myths and reality]. 2003 ·PubMed ·Marc Bourlière	1
18	Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B 1 1The Adefovir Dipivoxil International 461 Study Group includes the following: N. Afdhal (Beth Israel Deaconess Medical Center, Boston, MA); P. Angus (Austin and Repatriation Medical Centre, Melbourne, Australia); Y. Benhamou (Hopital La Pitie Salpetriere, Paris, France); M. Bourliere (Hopital Saint Joseph, Marseille, France); P. Buggisch (Universitaetsklinikum Eppendorf, Department of Medicine, Hamburg, Germany); P. Couzigou (Hopital Haut Leveque, Pessac, France); P. Ducrotte and G. Riachi (Hopital Charles Nicolle, Rouen, France); E. Jenny Heathcote (Toronto Western Hospital, Toronto, Ontario, Canada); H. W. Hann (Jefferson Medical College, Philadelphia, PA); I. Jacobson (New York Presbyterian Hospital, New York, NY); K. Kowdley (University of Washington Hepatology Center, Seattle, WA); P. Marcellin (Hopital Beaujon, Clichy, France); P. Martin (Cedars-Sinai Medical Center, Los Angeles, CA); J. M. Metreau (Centre Hospitalier Universitaire Henri Mondor, Creteil, France); M. G. Peters (University of California, San Francisco, San Francisco, CA); R. Rubin (Piedmont Hospital, Atlanta, GA); S. Sacks (Viridae Clinical Sciences, Inc., Vancouver, Canada); H. Thomas (St. Mary’s Hospital, London, England); C. Trepo (Hopital Hôtel Dieu, Lyon, France); D. Vetter (Hopital Civil, Strasbourg, France); C. L. Brosgart, R. Ebrahimi, J. Fry, C. Gibbs, K. Kleber, J. Rooney, M. Sullivan, P. Vig, C. Westland, M. Wulfsohn, and S. Xiong (Gilead Sciences, Inc., Foster City, CA); D. F. Gray (GlaxoSmithKline, Greenford, Middlesex, England); R. Schilling and V. Ferry (Parexel International, Waltham, MA); and D. Hunt (Covance Laboratories, Princeton, NJ). 2003 ·Gastroenterology ·Marion G. Peters, Hie‐Won Hann, Paul Martin, E. Jenny Heathcote, Peter Buggisch, R Rubin, Marc Bourlière, Kris V. Kowdley, Christian Trépo, DF Gray, Mark Sullivan, K. Kleber, Ramin Ebrahimi, S. Xiong, Carol Brosgart	440
19	Hépatite chronique C traitement des groupes particuliers. 2002 ·Gastroentérologie Clinique et Biologique ·Marc Bourlière, Philippe Halfon, Isabelle Portal	1
20	Faut-il dépister l'hépatite C? Analyse socio(-)économique de différentes stratégies de dépistage de l'hépatite chronique C dans la population française. 1997 ·Gastroentérologie Clinique et Biologique ·Michel Rotily, Sandrine Loubière, Judith M. Nixon, Marc Bourlière, Philippe Halfon, J.P. Moatti	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact